Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 11Myeloid 6Lymphoid 5Other 1Classical hematology 1

Conditions

Obesity 11Mucositis 11Neoplasms 5Breast Neoplasms 5Polycystic Ovary Syndrome 4Dyspnea 4Sexual Dysfunction, Physiological 3Leukemia 3Hematologic Neoplasms 3Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Pain 2Overweight 2Obesity, Morbid 2Obesity, Abdominal 2Motor Activity 2Lymphoma 2Intestinal Obstruction 2Infertility 2Hodgkin Disease 2Head and Neck Neoplasms 2Fatigue 2Constipation 2Xerostomia 1Weight Loss 1Urinary Incontinence 1Triple Negative Breast Neoplasms 1Stress Disorders, Post-Traumatic 1Stomatitis 1

Interventions

angiotensin I (1-7) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Graft vs Host Disease × Other × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡